Addex Pharmaceuticals S.A. (ADXN) Addex Convenes Annual General Meeting 2023
Addex Convenes Annual General Meeting 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Announces ADX71149 Phase 2 Epilepsy...
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Cohort 1 progressing through Part 2Cohort 2 recruiting patients Ad Hoc...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Reports Q1 2023 Financial Results and...
Addex Reports Q1 2023 Financial Results and Provides Corporate Update ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study CHF 5.6M ($...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Receives Nasdaq Notification...
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Shareholders Approve All Resolutions...
Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1, 2023 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Increases Issued Share Capital to...
Addex Increases Issued Share Capital to Create Treasury Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 15, 2023 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex mGlu2PAM Demonstrates Potential in...
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex GABAB Positive Allosteric Modulator...
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration Discovery collaboration on track to...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Therapeutics to Release Half-Year...
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023 Geneva, Switzerland, August 3, 2023 – (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Reports 2023 Half Year and Second...
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex’s Dipraglurant Development in...
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex mGlu2 NAM Cognition Program Receives...
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disorders Ad Hoc Announcement Pursuant...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Announces Plan to Implement ADS Ratio...
Addex Announces Plan to Implement ADS Ratio Change Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Completes ADS Ratio Change
Addex Completes ADS Ratio Change Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Announces Participation in the...
Addex Announces Participation in the Bio-Europe 2023 Conference Geneva, Switzerland, November 2, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Regains Nasdaq Listing Compliance
Addex Regains Nasdaq Listing Compliance Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex ADX71149 Epilepsy Phase 2 Study...
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - (SIX...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Therapeutics to Release Third Quarter...
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023 Geneva, Switzerland, November 23, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Convenes Extraordinary General Meeting
Addex Convenes Extraordinary General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Reports Q3 2023 Financial Results and...
Addex Reports Q3 2023 Financial Results and Provides Corporate Update ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024mGlu2 NAM...
View Article
